A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.


Updates from The Motley Fool

Latest updates on Celgene from Fool.com.  The Fool has written over 700 articles on Celgene.
The 1 Stock I'd Buy Right Now

In the vast ocean of stocks, big biotech Celgene is the one that looks most attractive to me at t...

3 Stocks for the Long Haul

These brand-name stocks could be your ticket to healthy long-term gains.



Stock Performance

View Interactive CELG Charts
Sponsored by

Key Data Points

Primary metrics and data points about Celgene.
Current Price: $124.05
Prev Close: $123.97
Open: $124.21
Bid: $123.77
Ask: $124.17
Day's Range: $123.20 - $124.33
52wk Range: $94.42 - $127.64
Volume: 3,537,063
Avg Vol 3,276,797
Market Cap: $97B
P/E (ttm): 46.61
EPS (ttm): $2.49
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Celgene.
CAPS Rating 5 out of 5
 
2197 Outperform
76 Underperform
CAPS All Stars
 
450 Outperform
13 Underperform

How do you think Celgene will perform against the market?



You pick for Celgene is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Mark J. Alles, CEO

91% Approve

Based on 28 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Celgene.

A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers